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ORIGINAL RESEARCH
Evaluation of Geographic Disparities in Cervical Cancer 
Survival Across Maine
Kaylee Underkofler, MD, MPH,1 Jason Lachance, MD2
1Department of Obstetrics & Gynecology, University of Rochester Medical Center, Rochester, NY, 2 Department of Obstetrics 
& Gynecology, Maine Medical Center, Portland, ME
Introduction:  National data suggests that there are geographic disparities in oncology care within the United States. 
It is unknown whether these disparities present a problem for women with gynecologic malignancies 
located in Maine.
Methods:  Data from each cervical cancer case diagnosed or treated under the MaineHealth system between 2007 
and 2011 were acquired from the MaineHealth Network Registry. Average annual incidence and 5-year 
survival were calculated for each county in Maine and mapped using geographic information systems 
software. Next, cases were divided into 2 groups: patients residing less than or equal to 60 miles from 
the sole gynecologic oncology practice in Maine and those residing over 60 miles from the practice. The 
5-year survival rates of each group were compared using chi-square testing. Demographics and risk 
factors of the 2 groups were compared with the 2-sample t-test or Fisher’s exact test.
Results:  The average annual incidence of cervical cancer in each county of Maine between 2007 and 2011 
ranged from 0 to 0.91 new cases per 10 000 female persons. The 5-year survival rate within each 
county ranged from 0% to 100%. The 5-year survival rate of women with cervical cancer residing less 
than or equal to 60 miles from the gynecologic oncology practice based in Maine was 63.0%, while the 
rate of those residing farther than 60 miles was 71.9% (P = .12).
Conclusions:  No significant geographic disparities in survival outcomes were found for women diagnosed with cervical 
cancer in Maine between 2007 and 2011. 
Keywords:  cancer, geographic disparities, rural health, gynecology
There is a growing emphasis on identifying and correcting disparities in health care.1 Multiple types of disparity exist, including gender, racial, 
socioeconomic status, and geographic location. 
Geographic disparities involve differences in health 
status or care access between 2 geographically 
defined populations.2 A recent study by Henley 
et al. illustrated the extent to which geographic 
disparities affect health care in the United States.3 
This study examined the difference in mortality 
from invasive cancers between metropolitan and 
nonmetropolitan rural counties across the nation. 
It concluded that rural counties, despite having 
lower incidence rates, had higher mortality rates 
than metropolitan counties. These findings suggest 
that geographic disparities in oncology care are a 
nationwide problem.
The state of Maine is primarily rural, with 61.3% of 
the population residing in areas comprising less 
than 2500 individuals.4 Geographic disparities are 
of particular concern in states like Maine due to 
the shortage of health care providers in rural areas 
and the location of specialty providers in urban 
areas.5 Gynecologic oncologists are among those 
specialty providers located to urban areas due to 
the need for volume, infrastructure for complex 
surgery, care coordination with other medical 
specialties, and ancillary facilities that can conduct 
chemotherapy infusion and radiation therapy. 
A recent study found that 36% of counties in the 
United States are located greater than 50 miles 
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from a gynecologic oncologist, putting 14.8 million 
women at risk of geographic disparities in care if 
they were to develop a gynecologic malignancy.6 
Given this location of gynecologic oncologists, and 
the reported national correlation between rurality 
and poor cancer outcomes, there is reasonable 
concern that geographic disparities might exist for 
women with gynecologic malignancies in Maine.3 
It is unknown whether patients with gynecologic 
malignancies living in the rural areas of Maine (or 
other states) face worse outcomes than those who 
reside closer to gynecologic oncology practices.
Geographic disparities might occur for women with 
many different types of cancer. However, there is 
greater concern for women with cervical cancer due 
to the nature of treatment. Cervical cancer is the third 
leading gynecologic malignancy in the developed 
world, and its treatment is complex.7 Treatment is 
multimodal, frequently requiring some combination 
of surgery, chemotherapy, and/or radiation therapy. 
Definitive chemoradiation for cervical cancer is 
complex. It typically involves daily pelvic radiation 
therapy for approximately 25 fractions and weekly 
cisplatin-sensitizing chemotherapy, followed by 
intracavitary brachytherapy.8 Surgery and radiation 
therapy can be done in only a limited number of 
facilities, with the lone gynecologic oncology 
practice in the state or an affiliated radiation 
oncologist typically located in an urban area. Due to 
the complexity of this care-delivery model, traveling 
to access services is particularly difficult for patients 
living in rural areas far from gynecologic oncology 
care and the necessary adjunctive services. A 
single-site study published in 2015 revealed that 
treatment completion for women with gynecologic 
cancers, while high overall, depended on the 
distance to treatment.9
We hypothesized that among women with cervical 
cancer living in Maine, survival rates may be worse 
for women residing far from their gynecologic 
oncologist when compared to those residing 
nearby.3 We conducted an observational pilot study 
to determine whether outcomes differ for a cohort of 
patients in Maine who were diagnosed with cervical 
cancer based on the distance of their residence 
from their primary gynecologic oncology practice. 
This sole practice was located in the southern and 
most populated part of the state.
METHODS
This study was approved by the Maine Medical 
Center Institutional Review Board in March 2018.
Data collection and management
Data by MaineHealth Oncology Information 
Services. All patients diagnosed or treated by 
a MaineHealth provider for a malignancy are 
automatically entered into this registry. The 
Maine Health Network Registry includes 89% of 
all gynecologic oncology patients in the state of 
Maine. All these patients were treated by the sole 
gynecologic oncology practice in Maine under the 
MaineHealth system and included in the study. The 
11% of patients not included in the registry sought 
treatment outside of the MaineHealth system and 
were excluded from the study.
All women residing in Maine who were diagnosed 
with cervical cancer and seen by a MaineHealth 
gynecologic oncologist between 2007 and 2011 
were eligible for inclusion in the study (n = 182). 
This date range was chosen to allow for calculation 
of 5-year survival for all patients over a 5-year time 
span. This span was chosen to increase the number 
of patients in the study and prevent changes in 
treatment recommendations over time from being 
a significant confounder. Patients were excluded 
from the study if their survival was unable to be 
calculated due to loss to follow-up (n = 26). Thus, 
156 patients were enrolled in the study. Variables 
extracted from each case included patient age, 
date of diagnosis, disease stage, zip code, county, 
vital status, time from diagnosis to most recent 
contact, insurance status, tobacco history, and 
race. Computed variables for each case included 
5-year survival status and distance in miles from 
zip code to the sole gynecologic oncology practice 
in Maine. Additional variables needed for incidence 
calculations included female population of each zip 
code and county, which were acquired from the 
United States Census Bureau.10 Data was stored 
and accessed using Microsoft Excel.
Data analysis
The average annual incidence of cervical cancer 
between 2007 and 2011 was calculated for each zip 
code and county in Maine. This calculation used the 
date of diagnosis for each case and 2010 Census 
tract data for the general female population of each 
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geographic unit. The average annual incidence of 
each zip code and county were also mapped to 
visually represent this data. Incidence rates were 
averaged over the 5-year study to protect patient 
confidentiality.
To explore the relationship between the distance 
to treatment and survival, the distance from the zip 
code to the primary gynecologic oncology practice 
for each patient was used to separate cases into 
2 study groups: patients residing greater than 60 
miles from the practice and patients residing less 
than or equal to 60 miles away. A distance cutoff 
of 60 miles was chosen as an estimate of the 
minimum distance that would burden patients 
needing to frequently obtain health care, and to 
ensure each group had a reasonable number of 
cases to maximize statistical power. The 5-year 
survival rate for each of the 2 groups was calculated 
using the 5-year survival status of each case within 
the groups. The survival rates were also calculated 
based on each zip code and county within Maine, 
and the rates were mapped using geographic 
information systems (GIS). Survival rates were 
averaged over the 5-year study to protect patient 
confidentiality.
Demographic and outcome data were summarized 
using descriptive statistics. Continuous data was 
shown as mean, and categorical data was shown 
as frequency (n, %). Differences between the 2 
distance groups were compared by chi-square (χ2) 
test or Fisher’s exact test as appropriate (categorical 
data), or by t-test (continuous data). A significance 
level of .05 was chosen for all tests. All statistical 
tests were done using the data analysis tools within 
Microsoft Excel.
Data mapping
Maps were produced with the GIS software Global 
Mapper by Blue Marble Geographics (Hallowell, 
ME) using the calculated average annual incidence 
rate and 5-year survival rate for each zip code and 
county in Maine. Because the small population 
sizes of several counties in Maine could jeopardize 
patient confidentiality and identification, maps of zip 
code data were not included in this report.
RESULTS
A select number of demographic variables and 
risk factors were compared between the 2 study 
groups: patients located less than or equal to 60 
miles from the sole gynecologic oncology practice 
and patients located greater than 60 miles away 
(Table 1). These variables included age, race, 
insurance status, cancer stage, and tobacco use 
history. The mean difference in age between the 2 
groups, calculated by 2-sample t-testing, was 0.69 
(P = .79, 95% CI [-4.31, 5.68]). Differences in race, 
insurance status, disease stage, and tobacco use 
history were compared using Fisher’s exact test (P 
= .59, .77, .70, and .86, respectively). There were 
no significant differences between the 2 groups.
The average annual incidence of cervical cancer 
in each county of Maine between 2007 and 2011 
ranged from 0 new cases per 10 000 female 
persons in Washington and Piscataquis Counties 
to 0.91 new cases per 10 000 female persons in 
Somerset County (Table 2, Figure 1). The 5-year all-
stage survival rate for women with cervical cancer 
in the state of Maine between 2007 and 2011 was 
67%. When examining each county of Maine, the 
5-year survival ranged from 0% in Oxford County to 
100% in Hancock and Aroostook Counties (Table 
2, Figure 2).
The 5-year survival rates of the 2 distance-based 
groups of cervical cancer patients were calculated. 
The 5-year survival rate of women residing less than 
or equal to 60 miles from the practice was 63.0%, 
while the rate of women residing farther than 60 
miles from the practice was 71.9% (χ = 1.30, P = 
.12).
DISCUSSION
Calculations and mapping of average annual 
incidence revealed that new cases of cervical 
cancer are fairly widespread across the state (Table 
1, Figure 1). The 2 counties with an incidence of 
0 new cases per 10 000 female persons are rural, 
and thus the low incidence may reflect smaller 
sample sizes rather than, for example, superior 
preventive care. Somerset County is rural and has 
a disproportionately high number of new cervical 
cancer cases. While local needs assessments in 
this area may help to determine the cause of this 
high incidence rate, the incidence in rural counties 
should be interpreted with caution. Given the 
small overall population, these rates are generally 
unstable over time.11
Survival maps produced with GIS did not suggest 
a correlation between distance to the primary 
gynecologic oncology practice and 5-year survival. 
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In fact, the highest 5-year survival rate was in 
the farthest county (Aroostook), while the lowest 
rate was in the county much closer to treatment 
centers (Oxford). This observation contradicts the 
hypothesis that survival rates would be lower for 
those who reside farther from care.
Statistical comparison of 5-year survival rates 
between the 2 study groups further supported 
that survival rates are not lower for patients with 
cervical cancer who reside farther from care in 
Maine. We were surprised that the 5-year survival 
rate appeared higher for patients residing further 
from care. However, further analysis using chi-
square testing yielded a P value of .12, indicating 
that there was no significant difference in survival 
between the 2 study groups. Of note, both survival 
rates are fairly consistent with the national 5-year 
survival rate for all-stage cervical cancer of 68%.12
This study did not reveal geographic disparities in 
the survival of cervical cancer patients in Maine. 
However, disparities occur elsewhere and may 
still exist throughout the state for patients with 
other gynecologic malignancies or serious chronic 
illnesses. Geographic disparities and research 
regarding them remain significant for this reason 
and several others. First, research addressing 
this phenomenon allows providers to identify 
whether the specific populations they serve may be 
vulnerable to disparities in care. A problem cannot 
be corrected if we do not know it exists. Second, 
studies that illustrate geographic variations in 
incidence and survival could indicate where more 
services are needed. If differences in survival are 
detected, they could help to establish oncology 
outreach clinics, introduce infusion capabilities or 
radiation modalities to existing health care centers, 
or invest in treatment housing (similar to the Ronald 
McDonald House model) for far-traveling patients.13 
Table 1. Comparison of selected demographics and risk factors between study groups. 
Variable
Patients  ≤ 60 miles from 
Maine GO
(n = 92)
Patients > 60 miles 
from Maine GO
(n = 64)
P value
Age, mean 51.83 51.14 .79
Race, no (%) .59
White 88 (96%) 64 (100%)
Black 2 (2%) 0 (0%)
Other 2 (2%) 0 (0%)
Insurance status, no (%) .77
Insured 79 (86%) 58 (91%)
Not insured 12 (13%) 6 (9%)
Unknown 1 (1%) 0 (0%)
Disease stage, no (%) .70
I 40 (43%) 25 (39%)
II 14 (15%) 10 (16%)
III 24 (26%) 15 (23%)
IV 13 (14%) 11 (17%)
Unknown 1 (1%) 3 (5%)
Tobacco use history, no (%) .86
History of use 51 (55%) 35 (55%)
No history of use 35 (38%) 26 (41%)
Unknown 6 (7%) 3 (5%)
*Percentages within subgroups that do not add up to exactly 100% are due to rounding.
GO, gynecologic oncologist.
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Geographic disparity studies are particularly 
valuable if different specialties find they need similar 
resources in remote locations. For example, if 
future geographic studies of gynecologic and other 
cancers suggest a need for a new chemotherapy 
infusion site in the northern regions of Maine, 
they could drive efforts to establish a new site for 
treatment.
There are limitations within this study. The first is 
the small sample size of cervical cancer patients 
and resulting limited statistical power. While we 
did observe every case of cervical cancer in the 
MaineHealth Network Registry between 2007 and 
2011, cervical cancer has a relatively low incidence 
in the United States thanks to the advent of the 
Pap smear.14 This low incidence, and thus small 
sample size, limited our comparison to 2 groups 
and also influenced the distance cutoff to maximize 
statistical power. The second limitation of this study 
involved the constraints of using registry data. 
The MaineHealth Network Registry only includes 
cases that are diagnosed or treated under the 
umbrella of MaineHealth, which, for gynecologic 
malignancies, is only 89% of the patients residing 
in Maine. Therefore, the study did not include every 
cervical cancer patient within the state of Maine. 
However, it did include every patient cared for by 
the sole gynecologic oncology practice based in 
Maine. Additionally, when using registry data, one 
must sacrifice data variables of interest for the 
convenience of access. For example, it would have 
been useful to examine other demographic and 
risk factor variables for cervical cancer patients, 
such as socioeconomic status and Pap smear 
history. It would have also been useful to know 
the treatment regimen for these patients and 
whether it influenced their survival. For example, in 
patients with intermediate-risk cervical cancer, we 
could consider whether geographic consideration 
influenced decisions between treating with radical 
hysterectomy or definitive chemoradiation. These 
variables were not recorded in the registry and could 
not be incorporated into analysis. Future efforts 
could involve a chart review, enabling these gaps 
to be filled. The third limitation of this study was loss 
to follow-up. Between 2007 and 2011, there were 
26 patients diagnosed with cervical cancer in Maine 
who could not be included in the analysis because 
their vital status could not be assured. Many of 
Table 2. Average annual incidence of cervical cancer and 5-year survival rates of patients with cervical 
cancer in Maine by county, 2007-2011.
County No. of new cases 
Female 
population
Average annual 
incidence per 
10 000 
female persons
No. of 
patients 
surviving 
5 years 
5-year 
survival rate
Androscoggin 15 55 036 0.55 12 80%
Aroostook 6 36 510 0.33 6 100%
Cumberland 40 145 062 0.55 24 60%
Franklin 6 15 722 0.76 5 83%
Hancock 3 27 753 0.29 3 100%
Kennebec 25 62 663 0.77 16 64%
Knox 3 20 067 0.30 1 30%
Lincoln 7 17 573 0.80 5 71%
Oxford 3 29 148 0.27 0 0%
Penobscot 3 78 039 0.08 2 67%
Piscataquis 0 8838 0.00 -- --
Sagadahoc 6 18 211 0.66 2 33%
Somerset 12 26 323 0.91 7 58%
Waldo 5 19 781 0.51 4 80%
Washington 0 16 658 0.00 -- --
York 22 101 128 0.44 17 77%
5
Underkofler and Lachance: Eval of Geo Disparities in Cervical Ca Survival Across ME
Published by MaineHealth Knowledge Connection, 2020
Figure 1. Map of average annual 
incidence of cervical cancer in Maine by 
county, 2007-2011.
Figure 2. Map of 5-year survival rates of 
patients diagnosed with cervical cancer 
in Maine by county, 2007-2011. Counties 
in white did not have any diagnosed 
cases.
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these patients were seen once for their surgery 
and not seen by their gynecologic oncologist again. 
Instead, they followed up in local rural settings due 
to geographic considerations. Therefore, these 
patients’ vital status was not updated in the registry. 
It does not appear that differences in distance to 
treatment were influential: 14 of the patients lost 
to follow-up resided within 60 miles of the Maine 
gynecologic oncology practice (13.2% of the nearby 
group), and 12 resided over 60 miles (15.8% of the 
far group).
CONCLUSION
We did not find a significant geographic disparity in 
the 5-year survival of patients with cervical cancer 
in Maine treated by MaineHealth between 2007 
and 2011.
Our findings do not suggest a need to expand 
resources for treatment of cervical cancer in rural 
areas of Maine based on survival outcomes alone. 
However, this outlook could change over time, 
especially as rural hospitals close their doors 
and more OB/GYNs leave rural practice.15,16 It is 
also possible that patients with other gynecologic 
malignancies face geographic disparities and 
may benefit from expanded services. Therefore, 
complacency is not recommended. Outcome 
assessments should be performed at regular 
intervals. It may also be beneficial to repeat this 
study with a focus on endometrial or ovarian 
cancer, gynecologic malignancies that are much 
more prevalent in Maine. This method could also be 
repeated on cervical cancer patients in a different 
geographical area, which might yield interesting 
results, albeit confirmatory or conflicting. With more 
available cases, there would be greater statistical 
power to identify a difference in outcomes if one 
truly exists.
Further investigation is required to determine 
whether geographic disparities exist for gynecologic 
oncology patients in Maine. If they exist, it is 
important that they are identified and that innovative 
methods are developed to reduce the impact of 
geography on patients’ health.
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